Atara Biotherapeutics, Inc.ATRAEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Adiumentum Capital Fund I LP | 19.99% | 1.1M | ▲ +13.29pp | 2024-09-05 |
| EcoR1 Capital, LLC | 9.99% | 493.5K | ▲ +0.09pp | 2024-11-14 |
| Redmile Group, LLC | 9.90% | 579.5K | flat | 2024-09-13 |
| Citadel Advisors LLC | 4.60% | 5.7M | ▼ -1.80pp | 2024-11-14 |
| The Vanguard Group | 3.18% | 180.7K | flat | 2024-11-12 |
| STATE STREET CORPORATION | 2.73% | 46.5M | — | 2024-01-22 |
| THE GOLDMAN SACHS GROUP, INC. | 0.60% | 580.6K | — | 2024-02-06 |
| Maverick Capital, Ltd. | 0.00% | 46.5M | — | 2024-02-14 |
| NOS. OF ABOVE PERSONS | 0.00% | 46.5M | ▼ -2.10pp | 2024-01-09 |
| BlackRock, Inc. | 0.00% | — | ▼ -7.00pp | 2024-07-08 |
| Wasatch Advisors LP | 0.00% | — | — | 2024-02-09 |
Insider Transactions
Net 90d: −$25.9K · buys $0 / sells $25.9KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-17 | Panacea Innovation Ltd | 10% Owner | Option exercise | 259.2K | $0.00 | $26 |
| 2026-03-09 | Nguyen AnhCo | President and CEO | Grant | 81.1K | $0.00 | $0 |
| 2026-03-09 | Grant-Huerta Yanina | Chief Accounting Officer | Grant | 20.3K | $0.00 | $0 |
| 2026-03-02 | Grant-Huerta Yanina | Chief Accounting Officer | Sell (open market) | 24 | $5.08 | $122 |
| 2026-03-02 | Grant-Huerta Yanina | Chief Accounting Officer | Sell (open market) | 1.6K | $5.08 | $8.1K |
| 2026-03-02 | Grant-Huerta Yanina | Chief Accounting Officer | Sell (open market) | 377 | $5.08 | $1.9K |
| 2026-03-02 | Grant-Huerta Yanina | Chief Accounting Officer | Sell (open market) | 100 | $5.08 | $508 |
| 2026-03-02 | Nguyen AnhCo | President and CEO | Sell (open market) | 198 | $5.08 | $1.0K |
| 2026-03-02 | Nguyen AnhCo | President and CEO | Sell (open market) | 58 | $5.08 | $295 |
| 2026-03-02 | Nguyen AnhCo | President and CEO | Sell (open market) | 1.3K | $5.09 | $6.6K |
1–10 of 11
Page 1 / 2